[go: up one dir, main page]

PE20241726A1 - Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits - Google Patents

Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits

Info

Publication number
PE20241726A1
PE20241726A1 PE2024000187A PE2024000187A PE20241726A1 PE 20241726 A1 PE20241726 A1 PE 20241726A1 PE 2024000187 A PE2024000187 A PE 2024000187A PE 2024000187 A PE2024000187 A PE 2024000187A PE 20241726 A1 PE20241726 A1 PE 20241726A1
Authority
PE
Peru
Prior art keywords
nav
branched
alkyl
linear
compound
Prior art date
Application number
PE2024000187A
Other languages
English (en)
Inventor
Gabriela Barreiro
Danilo Pereira De Sant’Ana
Luis Eduardo Reina Gamba
Carlos Alberto Manssour Fraga
Eliezer Jesus De Lacerda Barreiro
Lidia Moreira Lima
Original Assignee
Eurofarma Laboratorios S A
Univ Federal Do Rio De Janeiro – Ufrj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurofarma Laboratorios S A, Univ Federal Do Rio De Janeiro – Ufrj filed Critical Eurofarma Laboratorios S A
Publication of PE20241726A1 publication Critical patent/PE20241726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C07D241/32—(Amino-pyrazinoyl) guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Se refiere a compuestos n-acilhidrazonicos de formula I, o una sal, hidrato, solvato, y un isomero del mismo farmaceuticamente aceptable, donde R1 es H, halogeno, alquilo C1-6 ramificado o recto, entre otros; R2 y R3 se selecciona independientemente de H, halogeno, alquilo C1-C6 lineal o ramificado, entre otros; R4 es H, halogeno, alquilo C1-6 lineal o ramificado, alcoxi C1-6 lineal o ramificado, entre otros; R5 y R6 se seleccionan independientemente entre H y alquilo C1-6 lineal o ramificado. Un compuesto seleccionado es 6-(4-clorofenil)-N'-[(E)-(3,5-dimetoxifenil)metilideno]pirazina-2-carbohidrazida (Compuesto 1). Estos compuestos son inhibidores selectivos de canales de sodio dependientes de voltaje Nav 1.7 y/o Nav 1.8. Tambien se refiere a procedimientos de obtencion, a una composicion farmaceutica que comprende dicho compuesto, y su uso para tratar o prevenir patologias relacionadas con el dolor.
PE2024000187A 2021-08-02 2022-08-02 Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits PE20241726A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163228472P 2021-08-02 2021-08-02
PCT/BR2022/050303 WO2023010191A1 (pt) 2021-08-02 2022-08-02 Compostos n-acilidrazônicos inibidores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits

Publications (1)

Publication Number Publication Date
PE20241726A1 true PE20241726A1 (es) 2024-08-19

Family

ID=85153925

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000187A PE20241726A1 (es) 2021-08-02 2022-08-02 Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits

Country Status (14)

Country Link
US (1) US20240335442A1 (es)
EP (1) EP4382100A1 (es)
JP (1) JP2024528214A (es)
KR (1) KR20240105362A (es)
CN (1) CN118076348A (es)
AR (1) AR126669A1 (es)
BR (1) BR112024002228A2 (es)
CA (1) CA3227730A1 (es)
CO (1) CO2024002075A2 (es)
IL (1) IL310568A (es)
MX (1) MX2024001692A (es)
PE (1) PE20241726A1 (es)
UY (1) UY39881A (es)
WO (1) WO2023010191A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR131690A1 (es) * 2023-01-30 2025-04-23 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
WO2024159285A1 (pt) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3573306A (en) * 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
WO2003103665A1 (ja) * 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
KR20060019558A (ko) * 2003-05-27 2006-03-03 바스프 악티엔게젤샤프트 유해 곤충류 및 거미류의 방제를 위한 히드라존 유도체
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
CA2771472A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8518968B2 (en) * 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
WO2013123071A1 (en) * 2012-02-13 2013-08-22 Cleave Biosciences, Inc. Methods and compositions for jamm protease inhibition
CN103880707B (zh) * 2012-12-19 2016-04-13 上海交通大学医学院 Stat3小分子抑制剂及其应用
AU2014212509B2 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
EP2951168B1 (en) 2013-01-31 2017-01-04 Vertex Pharmaceuticals Incorporated Quinoline and quinoxaline amides as modulators of sodium channels
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
SG11201600082VA (en) 2013-07-10 2016-02-26 Vertex Pharma Fused piperidine amides as modulators of ion channels
US9163042B2 (en) 2013-12-13 2015-10-20 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
CN105481765A (zh) * 2015-04-15 2016-04-13 江苏艾凡生物医药有限公司 一类用于治疗心力衰竭的酰腙类衍生物
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
JP2019514879A (ja) 2016-04-20 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アシルスルホンアミドＮａＶ１．７阻害剤
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
MX393803B (es) 2017-06-20 2025-03-24 Raqualia Pharma Inc Derivados de amida como bloqueadores de nav1.7 y nav1.8
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
WO2020023802A1 (en) * 2018-07-25 2020-01-30 City Of Hope Parg inhibitors and method of use thereof
GEP20237568B (en) 2018-11-02 2023-11-27 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EP3894392A4 (en) * 2018-12-11 2022-08-24 Duke University COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CN110128343A (zh) * 2019-06-18 2019-08-16 四川省人民医院 一种酰肼类化合物
BR112021026395A2 (pt) 2019-06-27 2022-02-08 Glaxosmithkline Ip Dev Ltd Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8

Also Published As

Publication number Publication date
MX2024001692A (es) 2024-04-30
US20240335442A1 (en) 2024-10-10
EP4382100A1 (en) 2024-06-12
JP2024528214A (ja) 2024-07-26
KR20240105362A (ko) 2024-07-05
BR112024002228A2 (pt) 2024-04-30
CN118076348A (zh) 2024-05-24
CA3227730A1 (en) 2023-02-09
UY39881A (es) 2023-06-15
CO2024002075A2 (es) 2024-05-30
WO2023010191A1 (pt) 2023-02-09
IL310568A (en) 2024-03-01
AR126669A1 (es) 2023-11-01

Similar Documents

Publication Publication Date Title
CL2022000619A1 (es) Oxinitruro de piridina, método para su preparación y uso de este
PE20250021A1 (es) Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8
PE20230238A1 (es) Inhibidores de kras g12c
AR127235A1 (es) Pirazoloquinolinas inhibidoras de kras
PE20241127A1 (es) Compuestos triciclicos como inhibidores de kras
PE20241726A1 (es) Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits
PE20241068A1 (es) Moduladores de profarmacos de la via de estres integrada
PE20220705A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
HRP20090195T1 (hr) Inhibitori mitotičkih kinezina
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
AR037329A1 (es) Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
DK99691A (da) Dopamin-beta-hydroxylase-inhibitorer og fremgangsmaade til deres fremstilling
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
UY40234A (es) Compuestos heteroarilo para el tratamiento del dolor
UY40235A (es) Compuestos de heteroarilo para el tratamiento del dolor
CO2021003391A2 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
AR035254A1 (es) Derivados fluorquinolonicos de oxazolidinonas utiles como antibacterianos, procedimiento para su obtencion y su utilizacion para la preparacion de una composicion farmaceutica
AR052938A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
AR058180A1 (es) Indeno derivados, su preparacion y su uso como medicamentos